Table Of Content

AUTHOR INDEX (P = Proceedings) AARONS, L. see DAvis, J. D. Influence of endothelium and G. J., AYRTON, A. D., CLARKE, S. E. ABEL, S. M. see BROCKLESBY, K. surgical preparation on responses of & CHENERY, R. J. Characterisation AcurFfF, A. E. see HE, G.-W. human saphenous vein and internal of the cytochrome P450 enzymes AELLIG, W. H. Clinical pharmacology, thoracic artery to angiotensin II, 57 involved in the in vitro metabolism physiology and pathophysiology of Barry, M. G. see VEAL, G. J. of granisetron, 557 superficial veins—1, 181 Bascl, N. E., BROSEN, K., BOZHURT, BLoomer, J. C., CLARKE, S. E., AELLIG, W. H. Clinical pharmacology, A., ISIMER, A., SAYAL, A. & BALDwINn, S. J., SmitH, G. J., physiology and pathophysiology of KAYAALP, S. O. S-mephenytoin, Ayrton, A. D. & CHENERY, R. J. superficial veins—2, 289 sparteine and debrisoquine Characterisation of granisetron ALLAM, A. see GROVE, A. oxidation: genetic polymorphisms in metabolism in human liver ALM, C. see BERTILSSON, L. a Turkish population, 463 microsomes, 173P ANDERSON, J. see BARKER, J. E. BATEMAN, D. N. see ROBERTS, S. J. BOCHNER, F. see KERRY, N. L. ANDERSSON, A. see WALLEN, N. H. BAUMANN, J. see GONSCHIOR, A.-K. BONDESSON, U. see BERTILSSON, L. ANDERSSON, T., MINERS, J. O., BAUMANN, P., HATZINGER, M., Bowman, A. J., CHEN, C. P. L.-H. & VERONESE, M. E. & BirKETT, D. J. HEMMETER, U., SEIFRITZ, E., EAP, ForbD, G. A. Nitric oxide mediated Diazepam metabolism by human C. B. & Hotssoer, E. Letter to the venodilator effects of nebivolol, 199 liver microsomes is mediated by Editor: Influence of amesergide BozuHurtT, A. see BAScI, N. E. both S-mephenytoin hydroxylase treatment on the dextromethorphan BRApDBuRY, A. see WorBoys, P. D. and CYP3A isoforms, 131 test, 151 BratTrty, J. R. see Byrom, W. D. ANNUS, T. see Dyer, J. R. BausE, H. see SCHOLZ, J. BRAUN, F. see GONSCHIOR, A.-K. ARANKO, K., LuuRILA, H., BACKMAN, BAXTER, G. F. & YELLON, D. M. BRECKENRIDGE, A. M. see WALLER, J. T., NEUVONEN, P. J. & OLKKOLA, Review: Ischaemic preconditioning PC. K. T. The effect of erythromycin on of myocardium: a new paradigm for BREITHAUPT-GROGLER, K. see the pharmacokinetics and clinical cardioprotection?, 381 DE Mey, C. pharmacodynamics of zopiclone, BEAUMONT, K. C., MACRAE, P. V., BRENNAN, B. see Davis, J. D. 363 MILLER, C. M., WRIGHT, P. A. & BreTT, S. E. see CocKcROFT, J. R. ASTHANA, O. P. see PALIWAL, J. K. Smit, D. A. Pharmacokinetics of BREUEL, H.-P. see HEINE, P. R. AUSTIN, C. E. see SCADDING, G. K. zamifenacin in man and animals: BROCKLESBY, K. see HEwiItTT, P. AVIRAM, M. see KEIDAR, S. species differences in plasma BROCKLESBY, K., ABEL, S. M., Ayrton, A. D. see BALDWIN, S. J. protein binding, 179P Hortcukiss, S. A. M. & Back, D. J. AyrTONn, A. D. see BLOOMER, J. C. BEDDING, A. W. see PARIKH, R. Absorption and metabolism of Ayrton, A. D. see CLARKE, S. E. BECKER, K. see FuHR, U. hydrocortisone in human skin AYRTON, J. see EVANS, G. L. BEEDHAM, C. see RASHIDI, M. R. in vitro, 164P BEGAUD, B., MorIDE, Y., TUBERT- Brook, J. G. see KEIDAR, S. Back, D. J. see BROCKLESBY, K. BITTER, P., CHASLERIE, A. & BROSEN, K. see Bascl, N. E. BACK, D. J. see HOGGARD, P. G. HARAMBURJU, F. False-positives in Brown, V. see WATTS, P. Back, D. J. see VEAL, G. J. spontaneous reporting: should we BrucE-JONES, P. N. E., CROME, P. & BACKMAN, J. T. see ARANKO, K. worry about them?, 401 KALRA, L. Indomethacin and BADER, A., CHRISTIANS, U., CROME, O., BEITINGER, H. see STORM, G. cognitive function in healthy elderly FRUHAUF, N., ESSELMANN, H. & BELz, G. G. see DE MEY, C. volunteers, 45 SEWING, K. Fr. Use of organotypical BENDER, N. see COCKCROFT, J. R. BRUNDIN, R. M. see GRAHNEN, A. cultures of primary hepatocytes to BENITEZ, J. see BERTILSSON, L. Burke, M. D. see EKINs, S. study drug biotransformation, BENJAMIN, N. see LYons, D. BurkE, M. D. see MALEY, M. 158P BERNUS, I., DICKINSON, R. G., HOOPER, Bur, A. G. L., VAN DER MEER, A. D., | Ba.pwin, S. J. see BLoomer, J. C. W.D. & Eapie, M. J. Inhibition of VAN KLEEF, J. W., ZEIULMANS, ' BaLpwin, S. J. see CLARKE, S. E. phenobarbitone N-glucosidation by P. W. M. & GROEN, K. ' BALpwin, S. J., BLOOMER, J. C., SMITH, valproate, 411 Pharmacokinetics of the G. J., AYRTON, A. D., CLARKE, S. E. BERTAGNA, X. see COSTE, J. enantiomers of bupivacaine & CHENERY, R. J. The use of BERTILSSON, L., CARRILLO, J. A., DAHL, following intravenous sulphaphenazole as a potent and M.-L., LLERENA, A., ALM, C., administration of the racemate, 125 specific inhibitor of cytochrome BONDESSON, U., LINDSTROM, L., Byrom, W. D., ROTHERHAM, N. E. & P450 2C9 in vitro, 174P° RODRIGUEZ DE LA RuBIA, I., RAMOS, BratTrTy, J. R. Relationship between BALL, D. E., MCLAUGHLIN, W. S., S. & BENITEZ, J. Clozapine hypoglycaemic response and plasma SEYMouR, R. A. & KAMALI, F. disposition covaries with CYP1A2 concentrations of BTS 67 582 in Comparison of in vitro and in vivo activity determined by a caffeine healthy volunteers, 433 metabolism of phenytoin in the rat, test, 471 cat and man and susceptibility to BEssA, E. see JACQZ-AIGRAIN, E. CALDWELL, J. see GUILLOU, F. phenytoin-induced gingival BILLON, N. see DiMIER-DAVID, L. CALDWELL, J. see STRIBBLING, S. M. overgrowth, 168P BirKETT, D. J. see ANDERSSON, T. CARGILL, R. I., CouTiE, W. J. & BanGa, J. D. see Jacotort, B. BLoomMER, J. C. see BALDWIN, S. J. LipwortH, B. J. The effects of BARKER, J. E., ANDERSON, J., BLoomeER, J. C. see CLARKE, S.E. angiotensin II on circulating levels TREASURE, T. & PIPER, P. J. BLoomER, J. C., BALDWIN, S. J., SMITH, of natriuretic peptides, 139 585 586 Index CaRLILE, D. J., Dickins, M. & COLEMAN, R. see LANKESTER, D. J. measurement and of short-term Houston, J. B. Scaling factors for COLLIER, J. G. see O’ KANE, K. P. J. variability of blood pressure and predicting the kinetics of drug ConraD, J. see SEIFERT, R. D. heart rate in healthy volunteers, 109 metabolism in vivo using in vitro CorNnEL, M. C. see STURKENBOOM, DITTERICH, W. see THURAUF, N. systems, 177P M. C. J. M. Dusols, M. C. see Rey, E. A. CARRILLO, J. A. see BERTILSSON, L. COSTAGLIOLA, D. see DIMIER-DAVID, Duncan, M. W. see SEIDEMAN, P. CARROLL, K. see PEARS, J. S. L., CosTE, J., STRAUCH, G., LETRAIT, Dupret, J.-M. see DELOMENIE, C. CATTAN, D. see CHAPPEY, O. M. & BERTAGNA, X. Reliability of Dyer, J. R., DAvis, T. M. E., GIELE, C., CHADWICK, I. G. see ROWLAND, K. hormonal levels for assessing the ANNUS, T., GARCIA-WEBB, P. & CHAN, A. & YANG, J. M. The hypothalamic-pituitary- Rosson, J. The pharmacokinetics characterisation of sulphoxidation adrenocortical system in clinical and pharmacodynamics of quinine metabolites of moricizine using the pharmacology, 474 in the diabetic and non-diabetic isolated perfused rat liver, 167P COTREAU-BIBBO, M. M. see elderly, 205 CuapPey, O., NEIL, E., DERVICHIAN, Von MOLTKE, L. L. M., WAUTIER, J. L., SCHERRMANN, CouTig, W. J. see CARGILL, R. I. EapiE, M. J. see BERNUS, I. J. M. & CaTTAn, D. Colchicine CRISCUOLI, M. see WYLD, P. J. EAGLES, C. see HEAD, A. concentration in leukocytes of CROME, O. see BADER, A. Eap, C. B. see BAUMANN, P. patients with familial Mediterranean CROME, P. see BRUCE-JONES, P. N. E. EckERNAS, S.-A. see GRAHNEN, A. fever, 87 CRUuL, B. J. P. see VAN DONGEN, EpDwaARbDs, G. see GLAZIER, A. P. CHARLES, B. G. see CHULAVATNATOL, R. T. M. EDWARDS, I. see WarTTS, P. S. CurRIE, D. see McDevitt, D. G. EKINS, S., MuRRAY, G. I., BURKE, CHASLERIE, A. see BEGAUD, B. CUTLER, N. R. see SEIFERT, R. D. M. D., MARCHANT, N. M. & CHEN, C. P. L.-H. see BOWMAN, A. J. HAwkKswortH, G. M. Qualitative CHENERY, R. J. see BALDWIN, S. J. D’ATHIS, Ph. see REY, E. A. and quantitative comparison of CHENERY, R. J. see BLOOMER, J. C. DAHL, M.-L. see BERTILSSON, L. testosterone hydroxylation and 7- CHENERY, R. J. see CLARKE, S. E. Darsy, Y. C. see SCADDING, G. K. ethoxy-coumarin-O-deethylation in CHENERY, R. J. see LANKESTER, D. J. DARBYSHIRE, J. F. see GUILLOU, F. Sprague Dawley rat hepatocytes and CHIANG, C. P. see CHIANG, P. H. DarGIE, H. J. see CLAPPERTON, M. precision-cut liver slices, 164P CHIANG, P. H., Wu, S. N., Tsai, E. M., Datta, S. see VAN DEN BERG, A. A. ELLIs, S. W. see ROWLAND, K. Wu, C. C., SHEN, M. R., HUANG, Davis, J. D. see KHAN, A. Z. ESSELMANN, H. see BADER, A. C. H. & CHIANG, C. P. Adenosine Davis, J. D., BRENNAN, B., AARONS, L. Evans, G. L., AYRTON, J. & WILSON, modulation of neurotransmission in & Houston, J. B. Effect of K. Calculation of in vivo clearance penile erection, 357 norfloxacin on theophylline from in vitro data for a CHIPMAN, J. K. see LANKESTER, D. J. disposition: a comparison with other dihydropyridine calcium antagonist, CHOONARA, I. see PARKER, A. C. fluoroquinolones, 178P lacidipine, 162P CHOWIENCZYK, P. J. see COCKCROFT, Davis, T. M. E. see Dyer, J. R. J.R. Day, R. Meeting report: Asian Farr, S. J. see PARIKH, R. CHRISTIANS, U. see BADER, A. conference on clinical FARRAR, G., MITCHELL, A. M., HOOPER, CHRISTIANS, U. see GONSCHIOR, A.-K. pharmacology and therapeutics, 197 H., STEWART, F. & MALCOLM, S. L. CHULAVATNATOL, S. & CHARLES, B. G. Day, R. O. see SEIDEMAN, P. Prediction of potential drug Determination of dose-dependent Day, R. O. see WALKER, J. S. interactions of saquinavir (Ro 31- absorption of amoxycillin from DE JONG-VAN DEN BERG, L. T. W. see 8959) from in vitro data, 162P urinary excretion data in healthy STURKENBOOM, M. C. J. M. FISHER, A. C. see CLAPPERTON, M. subjects, 274 De KEYSER, P. see HERMANS, L. Forb, G. A. see BOwMAN, A. J. CLAPPERTON, M., McMurray, J., DE MEY, C., BREITHAUPT-GROGLER, K., FORESTER, E. R. see PARIKH, R. FISHER, A. C. & DARGIE, H. J. The ScHLOoos, J., PALM, D. & BELZz, FRANCIS, H. W. see OwEN, S. G. effect of angiotensin-converting G. G. Reproducibility and FREESTONE, S. see Li KAM Wa, T. C. enzyme inhibitors on human consistency of the responses to FRENCH-DUTCH FLUVASTATIN STUDY neutrophil chemotaxis in vitro, 53 supine bicycle ergometry: Group see JACOTOT, B. CLARKE, S. E. see BALDWIN, S. J. evaluation in conjunction with FRUHAUF, N. see BADER, A. CLARKE, S. E. see BLOOMER, J. C. B,-adrenoceptor occupancies, 480 Fucus, W., SENNEWALD, R. & KLOTA, CLARKE, S. E. see RASHIDI, M. R. DE RONZAN, J. see KUHN, J. M. U. Lansoprazole does not affect the CLARKE, S. E., BALDwin, S. J., DEBLANDER, A. see HERMANS, L. bioavailability of oral BLoomer, J. C., AYRTON, A. D. & DEL RE, G. see WYLD, P. J. contraceptives, 376 CHENERY, R. J. Cytochrome P450 DELOMENIE, “., GRANT, D. M., Funr, U., STAis, A. H., HARDER, S.., 2E1 and lauric acid @-1 MATHELIER-FUSADE, P., JACOMET, BECKER, K., LIERMANN, D., hydroxylation in rat, dog and human C., LEYNADIER, F., JACQZ-AIGRAIN, SCHOLLNHAMMER, G. & ROED, I.-S. liver microsomes, 174P E., ROZENBAUM, W., Absorption of ipsapirone along the CockcrorT, J. R., CHOWIENCZYK, P. J., KRISHNAMOORTHY, R. & DUPRET, human gastrointestinal tract, 83 Brett, S. E. & RITTER, J. M. Effect J.-M. N-acetylation genotype and FUNCK-BRENTANO, C. see DIMIER- of N°-monomethyl]-L-arginine on risk of severe reactions to Davi, L. kinin-induced vasodilation in the sulphonamides in AIDS patients, human forearm, 307 581 GaMZzU, E. see Muir, K. W. Cockcroft, J. R., CHOWIENCZYK, P. J., DERVICHIAN, M. see CHAPPEY, O. GARCIA-WEBB, P. see Dyer, J. R. Brett, S. E., BENDER, N. & RITTER, Dickins, M. see CARLILE, D. J. GESCHER, A. see HARGREAVES, M. B. J. M. Inhibition of bradykinin- DICKINSON, R. G. see BERNUS, I. GIELE, C. see DYER, J. R. induced vasodilation in human DIMIER-DAVID, L., BILLON, N., GIFFORD, L. A. see WITHEROW, L. E. forearm vasculature by icatibant, a COSTAGLIOLA, D., JAILLON, P. & GLazier, A. P., KOKWARO, G. O., potent B,-receptor antagonist, 317 FUNCK-BRENTANO, C. ISMAIL, S. & EDwarps, G. Effect of COHEN, C. see LAROCHE, F. Reproducibility of non-invasive an experimental malaria infection Index on the metabolism of phenacetin in HARGREAVES, M. B., GESCHER, A.., HUANG, C. H. see CHIANG, P. H. the rat isolated perfused liver, 167P Jones, B. C. & Situ, D. A. HYLAND, R. see JONES, B. C. Goeurs, M. see REY, E. A. Inhibition and induction of Gonscuior, A.-K., CHRISTIANS, U., cytochrome P-4502E1 by a range of IDLE, J. R. see WALKER, D. BRAUN, F., WINKLER, M., LINCK, A., aromatic compounds, 158P IRVINE, J. see GRANT, M. H. BAUMANN, J. & SEWING, K.-Fr. HARMATZ, J. S. see VON MOLTKE, L. L. IsIMER, A. see Bascl, N. E. Measurement of blood HARTMANN, A. see YEATES, R. A. ISMAIL, S. see GLAZIER, A. P. concentrations of FK506 HATZINGER, M. see BAUMANN, P. Iro, S. & Koren, G. A novel index for (tacrolimus) and its metabolites in HAWwKsworTH, G. M. see EKINS, S. expressing exposure of the infant to seven liver graft patients after the HAwkswortH, G. M. see MORSMAN, drugs in breast milk, 99 first dose by h.p.l.c.-MS and J. M. microparticle enzyme immunoassay He, G.-W., YANG, C.-Q., MACK, M. J., JACKSON, C. M. see GROVE, A. (MEIA), 567 AcurF, A. E. & RYAN, W. H. JACKSON, P. R. see ROWLAND, K. GouyETt, L. see REY, E. A. Interaction between endothelin and JACOMET, C. see DELOMENIE, C. GRAHAM, G. G. see SEIDEMAN, P. vasodilators in the human internal JACOTOT, B., BANGA, J. D., PFISTER, P., GRAHNEN, A., ECKERNAS, S.-A., mammary artery, 505 MEuRA, M. & FRENCH-DUTCH BRUNDIN, R. M. & LING- HEAD, A., MAXWELL, S., KENDALL, FLUVASTATIN STUDY GROUP. ANDERSSON, A. An assessment of M. J. & EAGLEs, C. Exercise Efficacy of a low dose-range of the systemic activity of single doses metabolism in healthy volunteers fluvastatin (XU 62-320) in the of inhaled fluticasone propionate in taking atenolol, high and low doses treatment of primary healthy volunteers, 521 of metroprolol CR/ZOK, and hypercholesterolaemia. A dose- GRANGER, N. see GRANT, M. H. placebo, 499 response study in 431 patients, 257 GRANT, D. M. see DELOMENIE, C. Hear, D. see PARKER, A. C. JACQZ-AIGRAIN, E. see DELOMENIE, C. GRANT, J. see WYLD, P. J. HEINE, P. R., WEYER, G., BREUEL, JACQZ-AIGRAIN, E., BESSA, E., GRANT, M. H. see Watts, P. H.-P., Muck, W., SCHMAGE, N. & MEDARD, Y., MIRCHEVA, Y. & GRANT, M. H., GRANGER, N. & KUHLMANN, J. Lack of interaction VILMER, E. Thiopurine MACDONALD, C. Comparative between diazepam and nimodipine methyltransferase activity in a menadione toxicity in primary during chronic oral administration French population: h.p.l.c. assay cultures and SV40-immortalised rat to healthy elderly subjects, 39 conditions and effects of drugs and hepatocytes, 172P HEssy, N. A. see WRIGHT, J. D. inhibitors, 1 GRANT, M. H., IRVINE, J., VASS, M. & HEMMETER, U. see BAUMANN, P. JAEGER, R. see TROVIK, T. S. MACDONALD, C. The effect of HENDERSON, G. I., PEREZ, A. B., YANG, JAILLON, P. see DimiER-DAVID, L. inducing agents on the xenobiotic Y., HAMBY, R. L., SCHENKEN, R. S. JAMIN, P. see LAROCHE, F. metabolising enzyme activities of & SCHENKER, S. Transfer of JARMAN, M. see MALEY, M. immortalised rat liver cells, 172P dideoxyinosine across the human JAYAKODY, R. L. see WEERASURIYA, K. GREENBLATT, D. J. see VON MOLTKE, isolated placenta, 237 JERLING, M., MERLE, Y., MENTRE, F. & Boe: HERMANS, L., DEBLANDER, A., DE MALLET, A. Population GROEN, K. see BurM, A. G. L. KEYSER, P., SCHEYS, I., LESAFFRE, pharmacokinetics of nortriptyline GrosskT, D. G. see Muir, K. W. E. & WESTELINCK, K. J. At during monotherapy and during Grove, A., ALLAM, A., MCFARLANE, equipotent doses, isradipine is better concomitant treatment with drugs L. C., MCPHATE, G., JACKSON, C. M. tolerated than amlodipine in patients that inhibit CYP2D6—an evaluation & Lipworth, B. J. A comparison of with mild-to-moderate with the nonparametric maximum the systemic bioactivity of inhaled hypertension: a double-blind, likelihood method, 453 budesonide and fluticasone randomized, parallel-group study, JEZEQUEL, S. see HARGREAVES, J. A. propionate in normal subjects, 527 335 JOHNSTON, N. R. see Li KAM Wa, T. C. Grover, P. K. see PALIWAL, J. K. Hewitt, P., BROCKLESBY, K. & JONES, B. C. see HARGREAVES, M. B. GUILLOU, F., DARBYSHIRE, J. F. & Hortcukiss, S. A. M. In vitro: JONES, B. C. see MORSMAN, J. M. CALDWELL, J. The enzymic basis for in vivo correlations in human skin JONES, B. C., HYLAND, R., SmiTH, D. A. the regioselective n-alkyl absorption of pharmaceutical & WALKER, D. K. Interaction of hydroxylation of 6(n-propyl)- agents, 163P dofetilide with cytochrome P450 chromone-2-carboxylic acid HIANG, T. C. see SENG, KHOO TAN, H. enzymes, 170P (6nPCCA) in the rat, 159P HJEMDAHL, P. see WALLEN, N. H. JONKMAN, J. H. G. see StoRM, G. GUMBLETON, M., OlE, S. & VEROTTA, HoGGarbD, P. G., VEAL, G. J., WILD, JORDE, R. see TROVIK, T. S. D. Pharmacokinetic- M. J. & Back, D. J. Screening for pharmacodynamic (PK-PD) drug interactions with zidovudine KAHAN, A. see LAROCHE, F. modelling in non-steady-state phosphorylation in vitro, 166P KALRA, L. see BRUCE-JONES, P. N. E. studies and arterio-venous drug HOLsBOER, E. see BAUMANN, P. KAMALI, F. see BALL, D. E. concentration differences, 389 HoNIJOL, N. M. see VAN DEN BERG, Kanmpr, G. & RITTER, J. M. Time- Gupta, R. C. see PALIWAL, J. K. A.A. dependent inhibition by glyceryl Hooper, H. see FARRAR, G. trinitrate of platelet aggregation Hampy, R. L. see HENDERSON, G. I. Hooper, W. D. see BERNUS, I. caused by U46619 (a thromboxane/ HAMUNEN, K. see OLKKOLA, K. T. Hortcukiss, S. A. M. see endoperoxide receptor agonist), 80 Haq, I. see ROWLAND, K. BROCKLESBY, K. KARBWANG, J. see NA-BANGCHANG, K. HARAMBURJU, F. see BEGAUD, B. Hotcukiss, S. A. M. see HEwITT, P. KAUL, S. see SEIFERT, R. D. HARDER, S. see FuHR, U. Houston, J. B. see CARLILE, D. J. KAYAALP, S. O. see Bascl, N. E. HARGREAVES, J. A., JEZEQUEL, S. & Houston, J. B. see Davis, J. D. KEIDAR, S., AVIRAM, M., MAoR, L., Houston, J. B. Effect of azole Houston, J. B. see HARGREAVES, J. A. OIKNINE, J. & BROOK, J. G. antifungals on human microsomal Houston, J. B. see WITHEROW, L. E. Pravastatin inhibits cellular metabolism of diclofenac and Houston, J. B. see Worsoys, P. D. cholesterol synthesis and increases midazolam, 175P Houston, J. B. see ZOMORODI, K. low density lipoprotein receptor 588 Index activity in macrophages: in vitro LEE, M. R. The antinatriuretic Safety Assessment of Marketed and in vivo studies, 513 action of y-glutamyl-5-hydroxy-L- Medicines (SAMM guidelines), 95 KENDALL, M. J. see HEAD, A. tryptophan is dependent on its MEHRA, M. see JACOTOT, B. Kerry, N. L., SomoGyl, A. A., decarboxylation to S5-hydroxy- MENTRE, F. see JERLING, M. BOcuHNER, F. & Mikus, G. The role tryptamine in normal man, 265 MERLE, Y. see JERLING, M. of CYP2D6 in primary and LIERMANN, D. see FunrR, U. Mikus, G. see KERRY, N. L. secondary oxidative metabolism of LIMPAIBUL, L. see NA-BANGCHANG, K. MILLER, C. M. see BEAUMONT, K. C. dextromethorphan: in vitro studies Linck, A. see GONSCHIOR, A.-K. MILLSON, D. S. see PEARS, J. S. using human liver microsomes, 243 LINDSTROM, L. see BEERTILSSON, L. MINERS, J. O. see ANDERSSON, T. Kuan, A. Z., Davis, J. D., Toon, S., LING-ANDERSON, A. see GRAHNEN, A. MIRCHEVA, Y. see JACQZ-AIGRAIN, E. LANGLEY, S., MUNAFO, A.., Lippi, A. see WYLD, P. J. MITCHELL, A. M. see FARRAR, G. PorcHET, H. & LE CoTONNEC, J.-Y. LipworTH, B. J. see CARGILL, R. I. MizuTANl, N., KOBAYASHI, T. & A study investigating the LipwortTH, B. J. see GROVE, A. WATANABE, T. Preliminary study of pharmacokinetic and LipworTH, B. J. see WHEELDON, N. M. the efficacy of xamoterol in pharmacodynamic equivalence of LLERENA, A. see BERTILSSON, L. bradycardia-tachycardia syndrome, two recombinant-human growth LOHRER, F. see SEIDEMAN, P. 285 hormone formulations administered LuuRILA, H. see ARANKO, K. MorIDE, Y. see BEGAUD, B. subcutaneously, 177P Lyons, D., STEWART, D., WEBSTER, J. MorsMAN, J. M., SmitH, D. A., JONES, KITTERINGHAM, N. R. see PARKER, & BENJAMIN, N. Angiotensin B. C. & HAWKSworTH, G. M. A.C. converting enzyme inhibition does Investigation of substrate structure- KLorTA, U. see Fucus, W. not affect the response to exogenous activity relationships for CYP2C9 KLorTz, U. see SCHOLZ, J. angiotensin II in the human forearm, using phenytoin and bis-triazole KoBAL, G. see THURAUF, N. 417 antifungal analogues, 156P KOBAYASHI, T. see MIZUTANI, N. MUCK, W. see HEINE, P. R. KOKWARO, G. O. see GLAZIER, A. P. MACDONALD, C. see GRANT, M. H. Muir, K. W., Grosset, D. G., GAMZU, KOOPMAN-KIMENAI, P. M. see MACFaDYEN, R. J. see SQuIRE, I. B. E. & Legs, K. R. Pharmacological VAN DONGEN, R. T. M. MACFADYEN, R. J., LEES, K. R. & REID, effects of the non-competitive KoopMans, P. P. see VAN DER VEN, J. L. Responses to low dose NMDA antagonist CNS 1102 in A.J. A.M. intravenous perindoprilat infusion normal volunteers, 33 Koren, G. see Ito, S. in salt deplete/salt replete Munapo, A. see KHAN, A. Z. KRISHNA, D. R. see SCHOLZ, J. normotensive volunteers, 329 MURALEEDARAN, R. see VAN DEN BERG, KRISHNAMOORTHY, R. see Mack, M. J. see HE, G.-W. A.A. DELOMENIE, C. MACRAE, P. V. see BEAUMONT, K. C. Murat, I. see Rey, E. A. KUHLMANN, J. see HEINE, P. R. MADDEN, S. see SPALDIN, V. Murray, G. I. see EKINS, S. Kun, J. M., LEGRAND, A., Ruiz, J. M., MALCOLM, S. L. see FARRAR, G. OBACH, R., DE RONZAN, J. & MALEY, M., WEAVER, R. J., JARMAN, NA-BANGCHANG, K., LIMPAIBUL, L., THomMaS, F. Pharmacokinetic and M. & BurKE, M. D. Comparison of THANAVIBUL, A., TAN-ARIYA, P. & pharmacodynamic properties of a tamoxifen and idoxifene metabolism KARBWANG, J. The long-acting formulation of the new by human liver microsomal pharmacokinetics of chloroquine in somatostatin analogue, lanreotide, cytochromes P450, 165P healthy Thai subjects and patients in normal healthy volunteers, 213 MALLET, A. see JERLING, M. with Plasmodium vivax malaria, 278 MANTEL, M. A. see VAN DER VEN, NEIL, E. see CHAPPEY, O. LANGLEY, S. see KHAN, A. Z. A.J. A.M. NEUVONEN, P. J. see ARANKO, K. LANKESTER, D. J., CHIPMAN, J. K., MAaok, I. see KEIDAR, S. NGUYEN, T. V. see WALKER, J. S. COLEMAN, R. & CHENERY, R. J. MARCHANT, N. M. see EKINS, S. NICHOLSON, A. N. see McDevitt, D. G. | Modelling of biliary excretion by MATHELIER-FUSADE, P. see NITYANAND, S. see PALIWAL, J. K. metabolism and accumulation DELOMENIE, C. studies in hepatocyte couplets, 170P MATTHEW, D. E. see MCLACHLAN, A. J. O’KaneE, K. P. J., Wess, D. J., LAROCHE, F., KAHAN, A., KAHAN, A., MAUNUKSELA, E.-L. see OLKKOLA, COLLIER, J. G. & VALLANCE, P. J. T. LeETRAIT, M. COHEN, C., JAMIN, P. & K. T. Local L-N°-monomethyl-arginine STRAUCH, G. Ketoprofen and MAXWELL, S. see HEAD, A. attenuates the vasodilator action of prednisolone do not modulate McDevitt, D. G. see WHEELDON, bradykinin in the human forearm, neutrophil CR1, CR3 and Fc RIII N. M. 311 expression in healthy volunteers, McDevitt, D. G., Currie, D., OBACH, R. see KUHN, J. M. 441 NICHOLSON, A. N., WRIGHT, N. A. & OlE, S. see GUMBLETON, M. LASSALE, C. see REY, E. A. ZETLEIN, M. B. Central effects of OIKNINE, J. see KEIDAR, S. LE CoTONNEC, J.-Y. see KHAN, A. Z. the diuretic bendrofluazide, 249 OLIVER, G. see REY, E. A. LEE, M. R. see Li KAM Wa, T. C. MCFAaRLANE, L. C. see GROVE, A. OLKKOLA, K. T. see ARANKO, K. Lees, K. R. see MACFADYEN, R. J. McLACHLAN, A. J., MATTHEW, D. E. & OLKKOLA, K. T., HAMUNEN, K., Legs, K. R. see Muir, K. W. ROWLAND, M. Application of a SEPPALA, T. & MAUNUKSELA, E.-L. Lees, K. R. see Squire, I. B. semi-parametric physiologic model Pharmacokinetics and ventilatory LEGRAND, A. see KUHN, J. M. to cyclosporin tissue distribution in effects of intravenous oxycodone LENNARD, M. S. see ROWLAND, K. the rat, 156P in postoperative children, LENNARD, M. S. see WEERASURIYA, K. MCLAUGHLIN, W. S. see BALL, D. E. 71 LESAFFRE, E. see HERMANS, L. McMurray, J. see CLAPPERTON, M. OOSTERHUIS, B. see STORM, G. Letralt, M. see Coste, J. McPHuateE, G. see GROVE, A. Owen, S. G., FRANCIS, H. W. & LetrRaIt, M. see LAROCHE, F. MEDARD, Y. see JACQZ-AIGRAIN, E. Roberts, M. S. Disappearance LEYNADIER, F. see DELOMENIE, C. MEDICINES CONTROL AGENCY, kinetics of solutes from synovial Li KAM WA, T. C., FREESTONE, S., COMMITTEE ON SAFETY OF. fluid after intra-articular injection, SAMSON, R. R., JOHNSTON, N. R. & Guidelines for company-sponsored 349 Index 589 PALIWAL, J. K., GROVER, P. K.., BERTILSSON, L. SENNEWALD, R. see FUCHS, W. ASTHANA, O. P., NITYANAND, S. & RoeD, I.-S. see Funr, U. SEPPALA, T. see OLKKOLA, K. T. GupTA, R. C. Excretion of ROTHERHAM, N. E. see Byrom, W. D. SEWING, K.-Fr. see BADER, A. centchroman in breast milk, 485 ROWLAND, K., ELLis, S. W., LENNARD, SEWING, K.-Fr. see GONSCHIOR, A.-K. PALM, D. see DE Mey, C. M. S. & TucKER, G. T. SEYMOUR, R. A. see BALL, D. E. PARIKH, R., SWEETLAND, J., FORSTER, Characterisation of the SHADER, R. I. see VON MOLTKE, L. L. E. R., BEDDING, A. W., Farr, S. J. enantioselective metabolism of SHEN, M. R. see CHIANG, P. H. & Smit, J. T. L. Ranitidine metoprolol by CYP2D6 expressed SKETT, P. see WoobE, E. bismuth citrate and ranitidine do not in yeast, 165P Situ, C. A. D. see WEERASURIYA, K. affect gastric emptying of a radio- ROWLAND, K., YEO, W. W., ELLIs, Situ, D. A. see BEAUMONT, K. C. labelled meal, 577 S. W., CHADwICcK, I. G., Haq, I., Situ, D. A. see HARGREAVES, M. B. PARIENTE-KHAYAT, A. see REY, E. A. LENNARD, M. S., JACKSON, P. R., Smith, D. A. see JonEs, B. C. ParK, B. K. see SPALDIN, V. RAMSAY, L. E. & TUCKER, G. T. SmitTH, D. A. see MorsMAN, J. M. PARKER, A. C., PRESTON, T., HEAF, D., Inhibition of CYP2D6 activity by SMITH, G. J. see BALDwin, S. J. KITTERINGHAM, N. R. & CHOONARA, treatment with propranolol and the Situ, G. J. see BLOOMER, J. C. I. Inhibition of caffeine metabolism role of 4-hydroxy propranolol, 9 SmitH, J. A. see RASHIDI, M. R. by ciprofloxacin in children with ROWLAND, M. see MCLACHLAN, A. J. SMITH, J. T. L. see PARIKH, R. cystic fibrosis as measured by the ROZARIO, C. J. see VAN DEN BERG, SmiTH, M. D. see Watts, P. caffeine breath test, 573 A. A. SOLLIE, F. A. E. see StoRM, G. Pears, J. S., TUERSLEY, M. D., ROZENBAUM, W. see DELOMENIE, C. SOMMER, W. see STorM, G. CARROLL, K., WEBB, W., RUANE, R. RUANE, R. J. see PEARS, J. S. Somocyl, A. A. see KERRY, N. L. J., MILLSON, D. S. & WILLIAMS, RUHNKE, M. see YEATES, R. A. SPALDIN, V., MADDEN, S., POOL, W. F., A. J. Tolerance and Ruiz, J. M. see KUHN, J. M. Woo LF, T. F. & Park, B. K. The pharmacokinetics of single oral RYAN, W. H. see HE, G.-W. effect of enzyme inhibitor on the doses of a novel §3-adrenoceptor metabolism and activation of tacrine agonist, ZD2079, in healthy male SAGER, G. see TROVIK, T. S. by human liver microsomes, 15 volunteers, 161P SAINT-MAURICE, C. L. see REY, E. A. Squire, I. B., MACFADYEN, R. J., LEEs, PEREZ, A. B. see HENDERSON, G. I. SAMSON, R. R. see L1 KAM Wa, T. C. K. R., STEWART-HILLIS, W. & REID, PFAFF, G. see YEATES, R. A. SARNOW, E. see YEATES, R. A. J. L. Haemodynamic response and PFISTER, P. see JACOTOT, B. Savva, D. see VAN DEN BERG, A. A. pharmacokinetics after the first dose PIPER, P. J. see BARKER, J. E. SAYAL, A. see Bascl, N. E. of quinapril in patients with POHL, S. see SCHOLZ, J. SCADDING, G. K., DARBY, Y. C. & congestive heart failure, 117 Pons, G. see REY, E. A. AustTIN, C. E. Effect of short-term SRAMEK, J. J. see SEIFERT, R. D. PooL, W. F. see SPALDIN, V. treatment with fluticasone Stais, A. H. see Funr, U. PORCHET, H. see KHAN, A. Z. propionate nasal spray on the STEWART, D. see Lyons, D. | PRESTON, T. see PARKER, A. C. response to nasal allergen challenge, STEWART, F. see FARRAR, G. 447 STEWART, M. B. see SEIFERT, R. D. ' RAMA PRABHU, N. V. see SCHENKEN, R. S. see HENDERSON, G. I. STEWART-HILLIS, W. see SQuirE, I. B. i VAN DEN BERG, A. A. SCHENKER, S. see HENDERSON, G. I. STorM, G., OOSTERHUIS, B., SOLLIE, _ Ramos, S. see BERTILSSON, L. SCHERRMANN, J. M. see CHAPPEY, O. F. A. E., VISSCHER, H. W., SOMMER, Ramsay, L. E. see ROWLAND, K. ScHEYS, I. see HERMANS, L. W., BEITINGER, H. & JONKMAN, | RANU, H. K. see WALKER, D. ScHLOOS, J. see DE MEy, C. J. H. G. Lack of pharmacokinetic RASHIDI, M. R., SMITH, J. A., CLARKE, SCHMAGE, N. see HEINE, P. R. interaction between vinpocetine and S. E. & BEEDHAM, C. Involvement SCHOLLNHAMMER, G. see FunR, U. oxazepam, 143 of rat and guinea pig aldehyde SCHOLZ, J., BAUSE, H., SCHULZ, M., STRAUCH, G. see CosTE, J. oxidase in the in vitro conversion of Kotz, U., KRISHNA, D. R., POHL, S. STRAUCH, G. see LAROCHE, F. famciclovir to penciclovir, 160P & SCHULTE AM Escu, J. STRIBBLING, S. M. & CALDWELL, J. RAWLINS, M. D. see WALLER, P. C. Pharmacokinetics and effects on Comparative elimination of allyl REID, J. L. see MACFADYEN, R. J. intracranial pressure of sufentanil in isothiocyanate (AITC) in rats and REID, J. L. see Squire, I. B. head trauma patients, 369 mice, 159P | Rey, E. A., PARIENTE-KHAYAT, A., SCHULTE AM EscH, J. see SCHOLZ, J. STRICKER, B. H. C. H. see GouYeET, L., VAUZELLE- SCHULZ, M. see SCHOLZ, J. STURKENBOOM, M. C. J. M. KERVROEDAN, F., PONS, G., SEIDEMAN, P., LOHRER, F., GRAHAM, STURKENBOOM, M. C. J. M., DE JONG- D’ AtTuis, Ph., DuBois, M. C., G. G., DUNCAN, M. W., WILLIAMS, VAN DEN BERG, L. T. W., VAN Murat, I., LASSALE, C., K. M. & Day, R. O. The Voorst-VADER, P. C., CORNEL, Goeurs, M., SAINT-MAURICE, C. L. stereoselective disposition of the M. C., STRICKER, B. H. C. H. & & OLIVER, G. Stereoselective enantiomers of ibuprofen in blood, WESSELING, H. Inability to detect disposition of ibuprofen blister and synovial fluid, 221 plasma etretinate and acitretin is a enantiomers in infants, 373 SEIFERT, R. D., STEWART, M. B., poor predictor of the absence of RITTER, J. M. see KAmpr, G. SRAMEK, J. J., CONRAD, J., KAUL, S. these teratogens in tissue after RITTER, J. M. see CockcrorT, J. R. & CuTLer, N. R. Pharmacokinetics stopping acitretin treatment, RoBERTS, M. S. see OWEN, S. G. of co-administered didanosine and 229 ROBERTS, S. J. & BATEMAN, D. N. The stavudine in HIV-seropositive male Susissi, A. see WYLD, P. J. use of nitrates, calcium channel patients, 405 SWEETLAND, J. see PARIKH, R. blockers and ACE inhibitors in SEIFRITZ, E. see BAUMANN, P. primary care in the Northern SENG, KHOO TAN H., THONG, C. E. & TAN-ARIYA, P. see NA-BANGCHANG, K. Region: a pharmacoepidemiological HIANG, T. C. Anti-emetic effect of THANAVIBUL, A. see NA-BANGCHANG, study, 489 high-dose metoclopramide vs K. ROBSON, J. see DYER, J. R. alizapride—a randomised crossover THOMAS, F. see KUHN, J. M. RODRIGUEZ DE LA RUBIA, I. see study, 282 THONG, C. E. see SENG, KHOO TAN H. 590 = Index THURAUF, N., DITTERICH, W. & KOBAL, VILMER, E. see JACQZ-AIGRAIN, E. than conventional doses of oral G. Different sensitivity of pain- VISSCHER, H. W. see STORM, G. nadolol on relative B,/B»- related chemosensory potentials VoN MOLTKE, L. L., GREENBLATT, D. adrenoceptor blockade, 103 evoked by stimulation with CO), J., COTREAU-BIBBO, M. M., WILD, M. J. see HoGGarRD, P. G. tooth pulp event-related potentials, HARMATZ, J. S. & SHADER, R. I. WILD, M. J. see VEAL, G. J. and acoustic event-related potentials Inhibitors of alprazolam metabolism WILLIAMS, A. J. see PEARS, J. S. to the tranquilizer diazepam, 545 in vitro; effect of serotonin- WILLIAMS, K. M. see SEIDEMAN, P. Toon, S. see KHAN, A. Z. reuptake-inhibitor antidepressants, WILSON, K. see EvANS, G. L. TRAUTMANN, M. see YEATES, R. A. ketoconazole and quinidine, 23 WINKLER, M. see GONSCHIOR, A.-K. TREASURE, T. see BARKER, J. E. VREE, T. B. see VAN DER VEN, WITHEROW, L. E., GIFFORD, L. A. & TROVIK, T. S., JAEGER, R., JORDE, R. & A.J. A.M. Houston, J. B. Kinetics of SAGER, G. Reduced sensitivity to VREE, T. B. see VAN DONGEN, R. T. M. phenytoin metabolism by rat hepatic B-adrenoceptor stimulation and microsomes in a two-compartment blockade in insulin dependent WALKER, D., RANU, H. K. & IDLE, J. R. incubation system, 168P diabetic patients with Discovery, characterisation and WoLF, C. R. see WEERASURIYA, K. hypoglycaemia unawareness, 427 importance of a novel metabolic Woop, S. M. see WALLER, P. C. Tsal, E. M. see CHIANG, P. H. pathway of ifosfamide, 157P WoobeE, E. & SKETT, P. No evidence TUBERT-BITTER, P. see BEGAUD, B. WALKER, D. K. see JONES, B. C. for dimethyl sulphoxide arresting Tucker, G. T. see ROWLAND, K. WALKER, J. S., NGUYEN, T. V. & Day, reciprocal changes in adrenergic Tucker, G. T. see WEERASURIYA, K. R. O. Clinical response to non- responses in hepatocytes, 161P TUERSLEY, M. D. see Pears, J. S. steroidal anti-inflammatory drugs in WOooLF, T. F. see SPALDIN, V. urate-crystal induced inflammation: Worpoys, P. D., BRADBURY, A. & VALLANCE, P. J. T. see O’ KANE, a simultaneous study of intersubject Houston, J. B. Ethoxycoumarin K. P. J. and intrasubject variability, 341 O-deethylase activity in precision VAN DEN BERG, A. A., HONJOL, N. M., WALLEN, N. H., ANDERSSON, A. & cut rat liver slices, 176P RAMA PRABHU, N. V., DaTTA, S., HJEMDAHL, P. Effects of treatments WRIGHT, J. D., HELSBy, N. A. & WARD, Rozario, C. J., MURALEEDARAN, R. with oral isosorbide dinitrate on S. A. The in vitro metabolism of & Savva, D. Analgesics and ENT platelet function in vitro: a double- proguanil: a role of CYP3A?, 169P surgery, 533 blind placebo-controlled study in WRIGHT, N. A. see McDevitt, D. G. VAN DER MEER, A. D. see BURM, patients with stable angina pectoris, WRIGHT, P. A. see BEAUMONT, K. C. A. G.L. 63 Wu, C. C. see CHIANG, P. H. VAN DER MEER, J. W. M. see WALLER, P. C., Woop, S. M.., Wu, S. see CHIANG, P. H. VAN DER VEN, A. J. A. M. BRECKENRIDGE, A. M. & RAWLINS, WYLD, P. J., GRANT, J., Lippi, A., VAN DER VEN, A. J. A. M., MANTEL, M. D. Why the Safety Assessment CRrISCUOLI, M., DEL RE, G. & M. A., VREE, T. B., KOOPMANS, of Marketed Medicines (SAMM) Susissi, A. Pharmacokinetics and P. P. & VAN DER MEER, J. W. M. guidelines are needed, 93 biochemical efficacy of idrapril Formation and elimination of Warp, S. A. see WRIGHT, J. D. calcium, a novel ACE inhibitor , sulphamethoxazole hydroxylamine WATANABE, T. see MIZUTANI, N. after multiple oral administration in after oral administration of Watts, P., SMITH, M. D., ZAMMITT, V., humans, 421 sulphamethoxazole, 147 EDWARDS, I., BROWN, V. & GRANT, VAN DONGEN, R. T. M., CRUL, B. J. P., M. H. Comparison of the effect of YANG, C.-Q. see HE, G.-W. KOOPMAN-KIMENAI, P. M. & VREE, medium composition on cytochrome YANG, J. M. see CHAN, A. T. B. Morphine and morphine- P450 and glutathione content and YANG, Y. see HENDERSON, G. I. glucuronide concentrations in urea synthesis in primary cultures of YEATES, R. A., RUHNKE, M., PFAFF, G., plasma and CSF during long-term rat and sheep hepatocytes, 171P HARTMANN, A., TRAUTMANN, M. & administration of oral morphine, WAUTIER, J. L. see CHAPPEY, O. SARNOW, E. The pharmacokinetics 271 WEAVER, R. J. see MALEY, M. of fluconazole after a single VAN KLEEF, J. W. see Burm, A. G. L. Wess, D. J. see O’KANE, K. P. J. intravenous dose in AIDS patients, VAN VoorST-VADER, P. C. see WEBB, W. see PEARS, J. S. 77 STURKENBOOM, M. C. J. M. WEBSTER, J. see Lyons, D. YELLON, D. M. see BAXTER, G. F. Vass, M. see GRANT, M. H. WEERASURIYA, K., JAYAKODY, R. L., YEO, W. W. see ROWLAND, K. VAUZELLE-KERVROEDAN, F. see Smitu, C. A. D., WoLF, C. R., Rey, E. A. Tucker, G. T. & LENNARD, M. S. ZAMMITT, V. see WATTS, P. VEAL, G. J. see HOGGARD, P. G. Debrisoquine and mephenytoin ZEILMANS, P. W. M. see BuRM, VEAL, G. J., WILD, M. J., BARRY, M. G. oxidation in Sinhalese: a population A. G. L. & Back, D. J. Effects of study, 466 ZETLEIN, M. B. see McDevitt, D. G. dideoxyinosine and dideoxycytidine WESSELING, H. see STURKENBOOM, ZomoropI, K. & Houston, J. B. on the intracellular phosphorylation M. C. J. M. Selective inhibition of diazepam of zidovudine in human WESTERLINCK, K. J. see HERMANS, L. metabolism by omeprazole in mononuclear cells, 323 WEYER, G. see HEINE, P. R. human liver microsomes, 175P VERONESE, M. E. see ANDERSSON, T. WHEELDON, N. M., McDevitt, D. G. & VerROTTA, D. see GUMBLETON, M. Lipworth, B. J. The effects of lower SUBJECT INDEX This index was compiled from the keywords (P = Proceedings) ACE inhibition, 421 CR/ZOK, 499 Ear anaesthesia, 533 ACE inhibitor, 53, 117, 489 CYP isoforms, 131 Effects on performance, 39 AIDS, 77 CYP1A2, 15, 471 Elderly, 205 AIDS patients, 579 CYP2C9, 156P Elderly healthy volunteers, 39 Absorption, 83, 164P, 274 CYP2D6, 9, 165P, 243, 453 Electroencephalogram, 545 Acitretin, 229 CYP3A, 169P, 557 Ewnax Model, 433 Adenosine, 357 Caffeine, 471 Enalapril, 417 Adenosine receptor, 357 Caffeine breath test, 577 Enalaprilat, 53 Adverse drug reactions, 401 Calcium channel blocker, 489 Enantiomers, 221, 373 Aggregation, 80 Cancer pain, 271 Enantioselective metabolism, 165P Albumin efflux, 349 Captopril, 53 Endothelin, 505 Aldehyde oxidase, 160P Carbidopa, 265 Endothelium, 57, 199, 307, 311 Aldosterone, 265 Cardiac arrhythmia, 167P Enzyme activities, 172P Alizapride, 282 Cardioprotection, 381 Enzyme induction, 158P Allergen challenge, 447 Carvedilol, 480 Enzyme inhibition, 158P Allyl isothiocyanate, 159P Celiprolol, 480 Equivalence, 177P Alprazolam, 23 Centchroman, 485 Erythromycin, 363 Amesergide, 151 Chemotaxis, 53 Ethnic differences, 466 Amlodipine, 335 Children, 577 Ethoxycourmarin O-deethylase, 176P Amoxycillin, 274 Chloroquine, 278 7-ethoxycoumarin-O-deethylation, Analgesics, 533 Cholesterol, 513 164P Angiotensin II, 57, 139, 417 Ciprofloxacin, 597 Etretinate, 229 Ankle oedema, 335 Cisplatin, 282 Event-related potential, 545 Antagonism, 480 Clearance, 99 Exercise, 480 Anti-cancer drug, 157P Clozapine, 471 Extensive metaboliser, 243 Anti-emesis, 282 Cognitive function, 45 Antihypertensive, 335 Colchicine, 87 FKS506, 567 Antimycotic drugs, 77 Colour duplex sonography, 357 FK506 metabolites, 567 Arterio-venous difference, 389 Coronary artery disease, 257 Famciclovir, 160P Asthma, 527 Corticosteroid, 527 Familial Mediterranean fever, 87 Atenolol, 499 Crystal-induced inflammation, 341 Fat oxidation, 499 Azapirones, 83 Cyclosporin, 156P Fatigue, 499 Azole antifungals, 175P Cystic fibrosis, 165P, 170P, 171P Fentanyl, 533 Cytochrome P 450, 577 Filtragometry, 63 B-adrenergic sensitivity, 427 Cytochrome P-450 2E1, 158P, 174P Fluconazole, 77 B-adrenoceptor, 103, 480 Cytochrome P450 2C9, 174P Fluoroquinolones, 178P B3-adrenoceptor antagonist, 161P Cytochrome P450-3A, 23 Fluoxetine, 23 B-adrenoceptor blockade, 499 Fluticasone propionate, 447, 521, 527 B-adrenoceptor blocker, 199 ddI, 23 Fluvastatin, 257 B-adrenoceptor partial agonist, 285 Debrisoquine, 237, 463, 466 Forearm blood flow, 311, 317, 411 B-receptors, 63 O-demethylation, 243 B-thromboglobulin, 317 Depression, 151 Gamma-L-glutamyl-5-hydroxy-L- BTS 67 582, 249, 433 Desmethylsertraline, 23 tryptophan, 265 Bendrofluazide, 249 Dextromethorphan, 151, 243 Gamma scintigraphy, 577 Benzodiazepine, 39, 545 Diazepam, 39, 131, 175P, 545 Gastric emptying, 577 Bicycle ergometry, 480 Diclofenac, 175P, 533 Genetic polymorphism, 1, 463 Biliary excretion, 170P Didanosine, 405 Gingival overgrowth, 168P Bioactivation, 15 Dideoxyinosine, 237 Glucosidation, 411 Bis-triazole antifungal analogues, 156P Dihydropyridine, 39 Glutathione, 171P Blood pressure, 109, 117, 329 Dihydropyridine calcium antagonist, Glyceryl trinitrate, 80, 311, 505 Bound drug transport, 349 162P Granisetron, 173P, 557 Bradycardia-tachycardia syndrome, Dimethy! sulphoxide, 161P Granulocytes, 87 285 Diuretic, 249 Bradykinin, 307, 317 Diurnal variation, 143 HF-capsule, 83 Breast milk, 485 Dofetilide, 170P HIV, 405 Breast-feding, 99 Dose-dependent, 274 HMG-CoA reductase inhibitor, 257 Budesonide, 527 Drug, 99 Human saphenous vein, 57 Bupivacaine enantiomers, 125 Drug biotransformation, 158P Heart failure, 117, 489 Buprenorphine, 533 Drug delivery device, 83 Heart rate, 109 Drug interactions, 39, 323, 376, 453 Hepatocyte couplets, 170P CNS 1102, 33 Drug metabolism, 177P, 567 Hepatocytes, 158P, 161P, 164P, 171P, CNS effects, 249 Drug—drug interaction, 405 172P 591 592 Index High dose metoclopramide, 282 Man, 317, 417, 577 274, 278, 363, 369, 389, 405, 421, Histamine, 447 Meeting report, 197 433, 505, 567 Hormonal levels, 474 Menadione, 172P Pharmacology, 289 Hormones, 376 Mephenytoin, 463 Pharmacovigilance, 401 H.p.l.c.-MS, 567 Metabolism, 164P, 513 Phenacetin, 167P Human forearm vasculature, 307 Method, 109 Phenobarbitone, 411 Human gastrointestinal tract, 83 Metoprolol, 165P, 480, 499 Phenocopying, 9 Human liver microsomes, 243, 557 Metoprolol sensitivity test, 427 Phenotype, 466 Human microsomes, 131 Michaelis-Menten, 274 Phenytoin, 156P, 168P Human milk, 99 Microsomal metabolism, 175P Physical exercise, 63 Human volunteers, 421 Microsomes, 173P Pituitary-adrenal axis, 474, 573 Hydrocortisone, 164P Midazolam, 175P, 369 Placenta, 237 5-hydroxytryptamine, 265 Modelling, 389 Plasma and CSF concentrations, 271 Hypercholesterolaemia, 257 Monitoring, 229 Plasma cortisol, 521 Hypertension, 489 Monocytes, 513 Plasma protein binding, 143 Hypoglycaemia unawareness, 427 Mononuclear cells, 87 Platelet aggregation, 63 Hysteresis, 389, 433 Moricizine, 167P Platelets, 80 Morphine, 533 Poisson distribution, 401 IDDM, 427 Morphine glucuronides, 271 Polymorphic oxidation, 466 Ibuprofen, 221, 341 Poor metaboliser, 243 Icatibant, 317 N-acetylation genotype, 579 Population pharmacokinetics, 453 Idoxifene, 165P N-demethylation, 243 Postmarketing surveillance, 229 Idrapril calcium, 421 N-methyl D-aspartate (NMDA), 33 Postoperative analgesia, 533 Ifosfamide, 157P N&-monomethyl-L-arginine, 307 Pravastatin, 513 Impotence, 357 Nadolol, 103 Pre-emptive analgesia, 533 In vitro metabolism, 23 Nalbuphine, 533 Prednisolone, 441 In-patient anaesthesia, 533 Nasal, 447 Prescribing, 489 Indomethacin, 45 Natriuretic peptides, 139 Primary care, 489 Inducing agents, 172P Nebivolol, 199 Proguanil, 169P Induction, 376 Neuroprotection, 33 Propranolol, 9, 480 Infant, 00 Neutrophil receptors, 441 6 (n-propyl)-chromone-2-carboxylic Infants, 373 Neutrophils, 53 acid, 159P Inhibition, 15, 376, 411 Nifedipine, 505 Prostacyclin, 57 Interaction, 143, 162P, 166P, 363, 411 Nimodipine, 39 Protein binding, 125, 179P Internal mammary artery coronary Nitrate, 489 Proteresis, 389 bypass, 505 Nitric oxide, 80, 199, 307, 311 Psychomotor effects, 363 Internal thoracic artery, 57 Nitric oxide synthase, 311 Intracellular phosphorylation, 323 Non-competitive antagonists, 33 Quinapril, 117 Intracranial pressure, 369 Non-insulin dependent diabetes Quinidine, 23 Intraoperative analgesia, 533 mellitus, 205 Quinine, 205 Intravenous ACE inhibition, 329 Non-steroidal anti-inflammatory drugs, Ipsapirone, 83 341 Racemate, 373 Irreversible binding, 9 Nonparametric maximum likelihood, Ranitidine bismuth citrate, 577 Ischaemia, 381 453 Ranitidine hydrochloride, 577 Ischaemic heart disease, 63, 489 Norfloxacin, 178P Receptor, 417 Ischaemic preconditioning, 381 Norfluoxetine, 23 Recombinant-human growth hormone, Isoprenaline sensitivity test, 427 Normal men, 213 177P Isosorbide dinitrate, 63 Nose anaesthesia, 533 Recovery, 533 Isradipine, 335 Nortriptyline, 453 Rectal application, 83 Regioselective n-alkyl hydroxylation, Ketoconazole, 23 Omeprazole, 175P 1S59P Ketoprofen, 441 Opioid, 369 Reliability, 474 Kidney, 265 Oral contraceptives, 376, 485 Renin-angiotensin system, 139, 329 Kinetics, 131 Oral hypoglycaemic, 433 Reproducibility, 480 Kinetics ibuprofen, 373 Oral morphine, 271 Risk, 229 Oxazepam, 143 L-NMMA, 311 Oxycodone, 71 Safety assessment of marketed LDL-receptor, 513 medicines, 93 LTC,, 447 PGD),, 447 SAMM guidelines, 95 Lacidipine, 162P Pain measurement, 545 Salbutamol, 103 Lanreotide, 213 Penciclovir, 160P Saline (placebo), 533 Lansoprazole, 376 Performance, 249 Saquinavir, 162P Lauric acid @-1 hydroxylation, 174P Perindoprilat, 329 Scaling factors, 177P Liquid meal, 577 Pethidine, 533 Selectivity, 103 Lipoproteins, 257 Pharmacodynamic variability, 341 Sensitivity, 229 Liver microsomes, 165P, 174P Pharmacodynamics, 39, 177P, 181, Serotonin antagonist, 151 Liver slices, 164P, 176P 205, 213, 389, 433 Serotonin-specific reuptake inhibitors, Pharmacokinetic-dynamic models, 71 23 Macrophages, 513 Pharmacokinetics, 39, 71, 77, 125, Sertraline, 23 Malaria, 167P, 278 161P, 168P, 177P, 179P, 205, 213, Sinhalese, 466 Index 593 Skin, 164P Sulphoxidation, 167P Triazole, 77 Skin absorption, 163P Superficial veins, 181, 289 Turkish population, 463 Slow-release formulation, 213 Suppression, 521 Sodium excretion, 265 Sustained release, 83 Urine cortisol, 521 Somatostatin analogue, 213 Synovial fluid kinetics, 349 Sparteine, 463 Systemic bioavailability, 527 Valproate, 411 Species differences, 179P Variability, 109 Spectral analysis, 109 Tacrine, 15 Veins, 199 Spontaneous reporting, 401 Talinolol, 480 Venoconstriction, 181 Stavudine, 405 Tamoxifen, 165P Venodilatation, 181 Stereoselectivity, 221 Teratogenicity, 229 Venous compliance, 181, 289 Substance P, 307 Testosterone hydroxylation, 164P Ventilation, 71 Sufentanil, 369 Theophylline, 178P Vinpocetine, 143 Sulphamethoxazole hydroxylamine, Therapeutic drug monitoring, 453, 567 147 Thiol, 53 ZD2079, 161P Sulphamethoxazole pharmacokinetics, Thiopurine methyltransferase, 1 Zamifenacin, 179P 147 Throat anaesthesia, 533 Zidovudine, 166P, 323 Sulphaphenazole, 174P Tissue distribution, 156P Zopiclone, 363 Sulphonamides, 579 Tolerance, 161P, 505